Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Direct Research and Development Expenses — Total by Quarter
Direct Research and Development Expenses — Total ($M) ($M)
Regeneron Pharmaceuticals Direct Research and Development Expenses — Total: $590M in Q3 2026, up 29.8% from a year earlier.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Total direct research and development expenses | 589.6 | 454.3 | 135.3 | 1,627.5 | 1,296.7 | 330.8”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up direct Research and Development Expenses — Total
- Direct Clinical R&D — Dupixent (dupilumab) ($M)28.8 · Q3 2026
- Direct Clinical R&D — Libtayo (cemiplimab) ($M)13.4 · Q3 2026
- Direct Clinical R&D — Fianlimab (anti-LAG-3 antibody) ($M)44.9 · Q3 2026
- Direct Clinical R&D — Lynozyfic (linvoseltamab, BCMAxCD3 bispecific) ($M)64.2 · Q3 2026
- Direct Clinical R&D — Ordspono (odronextamab, CD20xCD3 bispecific) ($M)57.9 · Q3 2026
- Direct Clinical R&D — Itepekimab (anti-IL-33 antibody) ($M)33.8 · Q3 2026
- Direct Clinical R&D — Pozelimab & Cemdisiran (anti-C5 / C5 siRNA) ($M)21.4 · Q3 2026
- Direct Clinical R&D — Trevogrumab (anti-GDF8 / myostatin antibody) ($M)11.5 · Q2 2026
- Direct Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M)16.5 · Q4 2025
- Direct R&D — Other Clinical Product Candidates & Earlier-Stage Research Programs ($M)263 · Q3 2026
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Direct Research and Development Expenses — Total ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-direct-tot
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?